9,761 Shares in AbbVie Inc. $ABBV Purchased by Financial Solutions Advisory Group Inc.

Financial Solutions Advisory Group Inc. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the first quarter, HoldingsChannel.com reports. The institutional investor purchased 9,761 shares of the company’s stock, valued at approximately $2,123,000.

Several other hedge funds have also bought and sold shares of the business. Dala Group LLC bought a new position in shares of AbbVie during the first quarter valued at approximately $297,000. Blue Fin Capital Inc. lifted its holdings in shares of AbbVie by 0.9% during the first quarter. Blue Fin Capital Inc. now owns 16,445 shares of the company’s stock valued at $3,577,000 after purchasing an additional 147 shares during the last quarter. Alpine Woods Capital Investors LLC boosted its position in shares of AbbVie by 7.5% in the 1st quarter. Alpine Woods Capital Investors LLC now owns 31,234 shares of the company’s stock worth $6,793,000 after purchasing an additional 2,190 shares in the last quarter. Allen Capital Group LLC boosted its position in shares of AbbVie by 12.0% in the 1st quarter. Allen Capital Group LLC now owns 3,807 shares of the company’s stock worth $828,000 after purchasing an additional 409 shares in the last quarter. Finally, Security Financial Services INC. grew its stake in shares of AbbVie by 6.1% in the 1st quarter. Security Financial Services INC. now owns 1,378 shares of the company’s stock worth $300,000 after buying an additional 79 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ABBV. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $269.29.

AbbVie Stock Down 2.4%

Shares of NYSE ABBV opened at $251.33 on Friday. The firm has a market cap of $444.05 billion, a P/E ratio of 71.00, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a twelve month low of $187.62 and a twelve month high of $267.47. The company has a 50 day moving average of $239.10 and a 200 day moving average of $224.05.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.12 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.